Ultragenyx Pharmaceutical (RARE) reported first-quarter 2025 loss of $1.57 per share, wider than the Zacks Consensus Estimate of a loss of $1.54. The company had incurred a loss of $2.03 per share in the year-ago quarter.Ultragenyx’s total revenues amounted to $139.3 million in the reported quarter, up 28% year over year, on the back of higher product sales. The top line, however, missed the Zacks Consensus Estimate of $142 million. (See the Zacks Earnings Calendar to stay ahead of market-making news.)The c ...

For the quarter ended March 2025, Ultragenyx (RARE) reported revenue of $139.29 million, up 28% over the same period last year. EPS came in at -$1.57, compared to -$2.03 in the year-ago quarter. As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately. Here is how Ultragenyx performed in the just reported quarter in terms of the metrics most widely monitored and projecte ...

Ultragenyx Pharmaceutical (RARE) Q1 2025 Earnings Call May 06, 2025 05:00 PM ET Company Participants Joshua Higa - VP - Investor RelationsEmil Kakkis - Founder, President, CEO & DirectorErik Harris - Executive VP & Chief Commercial OfficerHoward Horn - Executive VP of Corporate Strategy & CFOEric Crombez - Chief Medical Officer & Executive VPTazeen Ahmad - MD - US Equity ResearchGena Wang - MD - Biotech Equity ResearchYigal Nochomovitz - DirectorWill Soghikian - Vice President - Equity ResearchLiisa Bayko - ...

Ultragenyx Pharmaceutical (RARE) Q1 2025 Earnings Call May 06, 2025 05:00 PM ET Speaker0 Good afternoon, and welcome to the Ultragenyx First Quarter twenty twenty five Financial Results Conference Call. At this time, all participants are in a listen only mode. At the end of the prepared remarks, you will have an opportunity to ask questions during the Q and A portion of the call. It is now my pleasure to turn the call over to Joshua Higa, Vice President of Investor Relations. Speaker1 Thank you. We have iss ...

Corporate Presentation May 2025 Confidential and Proprietary Forward looking statements Cautionary note regarding forward-looking statements: This presentation contains forward-looking statements, including, but not limited to, statements regarding our expectations, estimates, assumptions, and projections regarding our future operating results and financial performance, including our expectations for profitability in 2027, anticipated cost or expense management, plans with respect to commercializing our pro ...

Core Insights - Ultragenyx Pharmaceutical Inc. reported total revenue of $139 million for Q1 2025, reflecting a 28% increase compared to Q1 2024, with Crysvita revenue at $103 million, a 25% increase year-over-year [4][8] - The company reaffirmed its 2025 financial guidance, projecting total revenue between $640 million to $670 million, with Crysvita revenue expected to be between $460 million to $480 million, and Dojolvi revenue between $90 million to $100 million [10][12] - The investigational treatment UX111 for Sanfilippo syndrome is on track for a Biologics License Application (BLA) action date set for August 18, 2025 [14] Financial Performance - Total revenues for Q1 2025 were $139 million, up from $108.8 million in Q1 2024, with significant contributions from Crysvita and Dojolvi [3][4] - Crysvita's product sales in Latin America and Türkiye reached $55 million, marking a 52% increase compared to the previous year [4][5] - Operating expenses totaled $282 million in Q1 2025, with research and development costs at $165.8 million [6][7] Net Loss and Cash Position - The net loss for Q1 2025 was $151 million, or $1.57 per share, an improvement from a net loss of $171 million, or $2.03 per share, in Q1 2024 [8][9] - As of March 31, 2025, the company had cash, cash equivalents, and marketable securities totaling $563 million, down from $745 million at the end of 2024 [9][29] Clinical Developments - The company is progressing with multiple clinical trials, including UX143 for osteogenesis imperfecta and GTX-102 for Angelman syndrome, with key interim analyses expected in mid-2025 [10][11] - The Phase 3 study for DTX401 is anticipated to submit a BLA in mid-2025, following positive results from the GlucoGene study [15][16] Strategic Focus - Ultragenyx aims to manage expenses while prioritizing investments in upcoming commercial launches and advancing multiple Phase 3 programs, which is expected to reduce net cash used in operations in 2025 compared to 2024 [10][12]